More info on connectivity
The Quo-Test® is a fully automated desktop point-of-care analyzer designed for easy and reliable HbA1c measurement for the monitoring and management of diabetes in a point-of-care setting such as diabetes clinics and doctors’ surgeries.
The Quo-Test HbA1c system is a fully automated hemoglobin A1c analyzer that uses patented boronate affinity fluorescence quenching technology to measure glycated hemoglobin from a 4 μl sample taken from a capillary or venous whole blood.
Sample results are available within four minutes and are dual-reported in IFCC and DCCT standard units (Mono S & JDS reporting are also available). Quo-Test uses the boronate affinity method which is recognized as interference free.
Quo-Test can store over 7,000 results which can be downloaded as text files to a PC via the integrated USB interface or through the Quo-Connect and EKF Link. Alternatively, results can be printed using a printer which connects via a serial port.
Step by step instructions displayed on the analyzers clear, multi-lingual display, reduces staff training time to a minimum, almost eradicating the opportunity for user-related errors.
Quo-Test is CE marked for the monitoring of HbA1c in diabetes patients.
For use with Quo-Test and Quo-Lab
Hemoglobin is an iron containing molecule present in red blood cells that is responsible for transporting oxygen around the body.
Glucose can bind irreversibly to hemoglobin via a process known as glycation. Hemoglobin that has glucose attached is known as glycated hemoglobin, often abbreviated to HbA1c or simply A1c.
Because red blood cells have a life span of 120 days (three months) measuring the level of glycated hemoglobin in blood effectively shows the average blood glucose level for the previous 6-8 weeks.
In conjunction with regular blood glucose monitoring, A1c tests can aid care providers in determining if a patient's treatment plan needs altering in any way to better control blood glucose levels.
Quo-Test analyzers and tests are calibrated and quality controlled using European Reference Laboratory supplied materials and are traceable to the IFCC reference method.
In an effort to standardize glycated haemoglobin results the AACC established the “National Glycohemoglobin Standardization Program” (NGSP) in 1996. In parallel the International Federation of Clinical Chemistry (IFCC) developed reference methods for glycated hemoglobin.
In 2006 and 2007, an international consensus between IFCC and AACC was agreed upon. The calibration and certification of laboratories and manufacturers to the same standards have improved the conformity of the results.
However, in practice differences can still be observed between technologies as well as between individual systems either because of the heterogeneity of hemoglobins, underlying different technologies (e.g. ion exchange, boronate affinity, immunoassay due to calibration drifts, or lot to lot variability.
This may result in differences in reported values. EKF Diagnostics follows the recommendations of the IFCC and NGSP to ensure that EKF instruments and reagents are accurately aligned and traceable to the reference method. See www.ngsp.org for more information.
Quo-Test uses boronate fluorescence quenching, a unique, patented technology, to deliver HbA1c results in four minutes.
The video (above) demonstrates how boronate fluorescence quenching technology measures glycated hemoglobin (HbA1c) from whole blood samples.
Based on well documented boronate affinity for glycated hemoglobin, BFQT has similar performance to the boronate affinity chromatography systems used in reference laboratories. Because BFQT does not require chromatographic separation, the methodology allows for fast, simple and accurate point of care HbA1c measurement.
The Quo-Test A1C Test using BFQT has been found to be unaffected by labile glycated hemoglobin and carbamylated hemoglobin (12.9%).
The following hemoglobin (Hb) variants have been analyzed and found not to affect the Quo-Test HbA1c test result: Hb AC, Hb AD, Hb AS, elevated fetal hemoglobin (up to 6,9 %) and ß-thalessemia.
Copyright © 2024 | Powered by Intergage